Table 3 Factors influencing the severity of lower urinary tract symptoms among HIV-positive patients
Variable | Odds ratio (95% CI) | p-value |
|---|---|---|
Sex | ||
Male | 2.75 (1.59–4.75) | < 0.001 |
Female | Ref | – |
Age group (years) | ||
> 49 | 3.02 (1.49–6.16) | 0.002 |
40–49 | 1.25 (0.56–2.83) | 0.586 |
< 40 | Ref | – |
Education level | ||
No formal | 1.21 (0.3–4.51) | 0.792 |
Primary | 0.66 (0.22–1.29) | 0.170 |
Secondary | 0.53 (0.31–1.29) | 0.180 |
College/University | Ref | – |
Marital status | ||
Married | 1.23 (0.72–2.09) | 0.445 |
Not married | Ref | – |
Employment status | ||
Formal | 1.47 (0.85–2.58) | 0.167 |
No formal | Ref | – |
CD4 count (cells/mm3) | ||
≤ 200 | 1.04 (0.56–2.32) | 0.885 |
201–499 | 0.71 (0.42–1.28) | 0.268 |
≥ 500 | Ref | – |
Viral load (copies/mL) | ||
Undetectable | 1.81 (0.75–4.41) | 0.187 |
< 1000 | 2.39 (0.53–9.97) | 0.252 |
≥ 1000 | Ref | – |
Antiretroviral therapy regimen | ||
TLD | 1.29 (0.11–9.1) | 0.781 |
TLE | 1.52 (0.24–21.27) | 0.847 |
ALD | 1.41 (0.14–9.36) | 0.941 |
ETA | 0.79 (0.16–6.71) | 0.778 |
Others | Ref | – |
Antiretroviral Therapy duration of use (years) | ||
> 10 | 3.03 (0.9–6.1) | 0.021 |
> 1 but ≤ 10 | 1.7 (0.3–3.54) | 0.545 |
≤ 1 | Ref | – |
HIV stage (WHO) | ||
Stage IV | 2.42 (0.9–3.4) | 0.047 |
Stage III | 1.01 (0.42–2.44) | 0.980 |
Stage II | 0.82 (0.34–1.99) | 0.671 |
Stage I | Ref | – |